Kmg mekophar

Overdose

Symptoms: abdominal pain, nausea, vomiting.

Treatment: first aid consists in washing the stomach, taking activated charcoal. If necessary — symptomatic therapy.

Contraindications

individual intolerance to the drug,

feverish states,

increased excitability,

acute psychotic reactions,

diseases of the hematopoietic organs, liver, kidneys, and gastrointestinal tract.

Incompatibilities

In combination with thiamine and pyridoxine, the drug is used to prevent and treat neurotoxic phenomena caused by drugs of the isonicotinic acid hydrazide group (isoniazid, ftivazid, etc.).

In myopathy and muscular dystrophy, the drug is more effective in combination with pachycarpine and glycocol.

Undesirable effects

There may be nausea, vomiting, agitation, the appearance of loose stools, with prolonged treatment-a decrease in the level of hemoglobin and the development of leukopenia.

Therapeutic indications

Coated tablets, Intestinal-coated tablets, Substance-powderPills

In complex therapy:

epilepsy, mostly minor seizures with equivalents,

somatogenic, involutional, intoxicating psychoses, reactive states with the phenomena of depression, exhaustion,

mental retardation in children, Down's disease, cerebral palsy, polio (acute and recovery periods),

progressive myopathy (in combination with pachycarpine or glycocol),

elimination and prevention of neurotoxic effects caused by drugs-derivatives of isonicotinic acid hydrazide.

In complex therapy:

epilepsy, mostly minor seizures with equivalents,

somatogenic, involutional, intoxicating psychoses, reactive states with the phenomena of depression, exhaustion,

mental retardation in children, Down's disease, cerebral palsy, polio (acute and recovery periods),

progressive myopathy (in combination with pachycarpine or glycocol),

elimination and prevention of neurotoxic effects caused by drugs-derivatives of isonicotinic acid hydrazide.

Pharmacotherapeutic group

Coated tablets, Intestinal-coated tablets, Substance-powderPills
  • Nootropics
  • Proteins and amino acids
  • Detoxifying agents, including antidotes
  • Other neurotropic agents

Pharmacodynamic properties

Coated tablets, Intestinal-coated tablets, Substance-powderPills

Glutamic acid belongs to the group of non-essential amino acids, in particular, to the neurotransmitter amino acids that stimulate the transmission of excitation in the synapses of the central nervous system. Glutamic acid is involved in the metabolism of carbohydrates, proteins, oxidative processes, skeletal muscle contraction, detoxification and elimination of ammonia from the body, promotes the synthesis of acetylcholine and ATP, and the transfer of potassium ions. Increases the body's resistance to hypoxia.

KMG Mekophar belongs to the group of non-essential amino acids, in particular, to the neurotransmitter amino acids that stimulate the transmission of excitation in the synapses of the central nervous system. KMG Mekophar is involved in the metabolism of carbohydrates, proteins, oxidative processes, skeletal muscle contraction, detoxification and elimination of ammonia from the body, promotes the synthesis of acetylcholine and ATP, and the transfer of potassium ions. Increases the body's resistance to hypoxia.

Pharmacokinetic properties

Coated tablets, Intestinal-coated tablets, Substance-powderPills

Glutamic acid is well absorbed when ingested and penetrates through the BBB and cell membranes. About 4-7% of it is excreted in the urine in unchanged form, the remaining amount is utilized in the process of metabolic transformations.

KMG Mekophar is well absorbed when taken orally and penetrates through the BBB and cell membranes. About 4-7% of it is excreted in the urine in unchanged form, the remaining amount is utilized in the process of metabolic transformations.

Qualitative and quantitative composition

Glutamic Acid

Dosage (Posology) and method of administration

Inside, 2-3 times a day, adults in a single dose-1 g, children aged 3-4 years-0.25 g, 5-6 years-0.4 g, 7-9 years-0.5-1 g, 10 years and older-1 g.

The course of treatment - from 1-2 months to 6 months-1 year.